Dr. Megan Kruse, top Cleveland Clinic breast medical oncologist, discusses two studies that caught her eye at the ESMO 2017 conference in early September.
Megan Kruse, MD, of Cleveland Clinic discusses two important CDK 4/6 breast cancer studies that were presented at the ESMO 2017 conference. The first looks at abemaciclib, a CDK inhibitor, combined with aromatase inhibitor in the first line treatment for women with hormone receptor-positive and HER2-negative metastatic breast cancer.
The second study looks at the use of palbociclib in pre-operative settings for women with hormone receptor-positive disease.
